In summary, we demonstrated that the radioligand [18F]SDM-16 had high uptake in mouse brain, and APP/PS1 mice showed lower tracer uptake than WT mice, supporting the use of [18F]SDM-16 in preclinical AD drug discovery and development. Here, APP is linked to Alzheimer disease.